International collaboration to assess the risk of Guillain Barre Syndrome following Influenza A (H1N1) 2009 monovalent vaccines

Caitlin N Dodd, Silvana A Romio, Steven Black, Claudia Vellozzi, Nick Andrews, Miriam Sturkenboom, Patrick Zuber, Wei Hua, Jan Bonhoeffer, James Peter Buttery, Nigel Crawford, Genevieve Deceuninck, Corrine de Vries, Philippe De Wals, M Victoria Gutierrez-Gimeno, Harald Heijbel, Hayley Hughes, Kwan Hur, Anders Hviid, Jeffrey KelmanTehri Kilpi, S K Chuang, Kristine K Macartney, Melisa Rett, Vesta Richardson Lopez-Callada, Daniel Salmon, Francisco Gimenez Sanchez, Nuria Sanz, Barbara Silverman, Jann Storsaeter, Umapathi Thirugnanam, Nicoline van der Maas, Katherine Yih, Tao Zhang, Hector Izurieta

Research output: Contribution to journalArticleResearchpeer-review

87 Citations (Scopus)


The global spread of the 2009 novel pandemic influenza A (H1N1) virus led to the accelerated production and distribution of monovalent 2009 Influenza A (H1N1) vaccines (pH1N1). This pandemic provided the opportunity to evaluate the risk of Guillain?Barre syndrome (GBS), which has been an influenza vaccine safety concern since the swine flu pandemic of 1976, using a common protocol among high and middle-income countries. The primary objective of this project was to demonstrate the feasibility and utility of global collaboration in the assessment of vaccine safety, including countries both with and without an established infrastructure for vaccine active safety surveillance. A second objective, included a priori, was to assess the risk of GBS following pH1N1 vaccination
Original languageEnglish
Pages (from-to)4448 - 4458
Number of pages11
Issue number40
Publication statusPublished - 2013

Cite this